

Special Issue

Human Protein Kinases: Development of Small- Molecule Therapies

Message from the Guest Editor

Protein kinases play essential roles in the human body. Changes in kinase expression and/or function due to mutations, overexpression, or loss of function have been linked with diverse diseases. Accordingly, the modulation of kinases is viewed as a therapeutic strategy. The development of small-molecule kinase inhibitors has resulted in 71 FDA-approved drugs. Kinase activation is another approach that may have utility in cases where loss of function propagates disease. Finally, the degradation of kinases is an alternative strategy that is quickly gaining traction in diseases where kinase overexpression drives pathology. As kinases are amongst the most tractable proteins in the human proteome, the design and development of small molecules targeting them is an attractive avenue to modulate their function in human disorders. This Special Issue, "Human Protein Kinases: Development of Small-Molecule Therapies", welcomes submissions of original research articles and reviews on the development and use of kinase-targeting small molecules for a therapeutic endpoint.

Guest Editor

Dr. Alison D. Axtman

Structural Genomics Consortium, UNC Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Deadline for manuscript submissions

30 December 2024



Kinases and Phosphatases

an Open Access Journal
by MDPI



mdpi.com/si/141459

Kinases and Phosphatases
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
kinasesphosphatases@mdpi.com

mdpi.com/journal/

[kinasesphosphatases](https://mdpi.com/journal/kinasesphosphatases)





Kinases and Phosphatases

an Open Access Journal
by MDPI



[mdpi.com/journal/
kinasesphosphatases](https://mdpi.com/journal/kinasesphosphatases)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Mauro Salvi

Department of Biomedical Sciences, University of Padova, Padova, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

first decisions in 16 days; acceptance to publication in 5.8 days (median values for MDPI journals in the first half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.